Pharmaceutical Executive
As the market for specialty and generic products continues to become more competitive and pricing pressures increase, the 505(b)(2) pathway may allow companies more options to diversify their portfolios.
Doug Balogh
Advertisement
Articles by Doug Balogh
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty
2
Pharmaceutical Executive Daily: Shah Capital's Plan to Vote Against Novavax Board Nominees
3
Medical Supply Chains at Risk Over Escalating Conflicts in Iran: Report
4
Novavax Stock Increases as Shah Capital Plans to Vote Against Board Nominees
5